IP Library Granted Patent US 12698313
Granted Patent B2
US 12698313 · App. 18/040,643 · Granted Aug 4, 2026

Bone morphogenetic protein-9 and -10 variants with enhanced therapeutic effect due to reduced side effects of ectopic ossification and pharmaceutical composition comprising same

Inventors: Chong-Pyoung Chung (Seoul, KR); Yoon Jeong Park (Seoul, KR); Jue-Yeon Lee (Gyeonggi-do, KR); Gook-Jin Yoon (Seoul, KR); Dong Woo Lee (Seoul, KR)
Assignee: NIBEC CO., LTD.
C07K14/51A61K47/6811C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12698313
App. No.
18/040,643
Granted
Aug 4, 2026
Kind
B2
Abstract

The present invention relates to a BMP-9 variant and a derivative thereof. The variant stimulates endothelial cell-specific signaling, but does not stimulate ectopic ossification-related signaling, as compared to wild-type BMP-9, and thus has the effects of enhancing therapeutic effects on various diseases, including tumors, cardiovascular disease, fibrotic diseases, inflammatory diseases, metabolic diseases, and autoimmune diseases, and reducing side effects.

Claims (10)

1 . A bone morphogenetic protein-9 (BMP-9) variant represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 2 to 28.

2 . A BMP-9 variant-Fc fusion protein in which an Fc fragment of an immunoglobulin is linked to the BMP-9 variant according to claim 1 .

3 . The BMP-9 variant-Fc fusion protein according to claim 2 , wherein the Fc fragment of the immunoglobulin is represented by the amino acid sequence of SEQ ID NO: 30.

4 . The BMP-9 variant-Fc fusion protein according to claim 2 , wherein the BMP-9 variant and the Fc fragment of the immunoglobulin are linked to each other via a linker.

5 . The BMP-9 variant-Fc fusion protein according to claim 4 , wherein the linker is represented by the amino acid sequence of SEQ ID NO: 31.

6 . A pharmaceutical composition comprising the BMP-9 variant according to claim 1 or the BMP-9 variant-Fc fusion protein according to claim 2 as an active ingredient.

7 . The composition according to claim 6 , comprising a pharmaceutically acceptable carrier.

8 . The composition according to claim 7 , wherein the pharmaceutically acceptable carrier is selected from among saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more thereof.

9 . The composition according to claim 6 , comprising a pharmaceutically acceptable adjuvant.

10 . The composition according to claim 9 comprising at least one selected from the group consisting of excipients, diluents, dispersants, buffers, antimicrobial preservatives, bacteriostats, surfactants, binders, lubricants, antioxidants, thickeners, and viscosity modifiers.